Plain-English translation of NCT06100237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether or , when combined with a medication called Daratumumab, can help prevent or delay smoldering myeloma from progressing to active multiple myeloma. Smoldering myeloma is an early stage of blood cancer where cancer cells are present but haven't yet caused serious symptoms. The study will enroll about 50 patients and test two different drug combinations to see which works best at slowing disease progression.
Right now, patients with smoldering myeloma often wait and watch their condition closely without treatment, but many eventually develop active myeloma that requires intensive therapy. This trial is testing whether treating early with these medications can delay or prevent that progression, potentially improving outcomes and quality of life.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive one of two drug combinations given by injection or infusion on a set schedule. The first group of patients will receive combined with Daratumumab, and based on how well that works, the second group may receive combined with Daratumumab instead. You will have regular visits for blood tests, physical exams, and bone marrow biopsies to monitor how the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States